HDAC9 and hepatocellular carcinoma: However, Kang et al. [320] showed that Cur does not display any effect on the HDAC activity in human hepatoma Hep3B cells, but was able to inhibit the HAT activity in vitro and in vivo and the histone acetylation in the absence or presence of the specific HDAC inhibitor, the trichostatin A, to decrease or enhance the ROS production, and to induce the histone hypoacetylation in vivo.